Sleep Apnea Treatments Compared: CPAP vs. Oral Appliance vs. Surgery
Medically reviewed by Medical Advisory Board Last reviewed 2026-06-18
Evidence-based comparison of OSA treatment options by efficacy and compliance
CPAP is the gold standard for obstructive sleep apnea, but adherence hovers at 50%. Oral appliances, positional therapy, surgery, and emerging options like Inspire offer alternatives — each with trade-offs in efficacy, cost, and compliance.
Treating sleep apnea effectively requires matching the treatment to the severity of disease, the anatomical cause, and — critically — the patient's ability to adhere to therapy long-term. The most effective treatment is the one you actually use consistently.
While CPAP reduces AHI to near-zero in compliant users, real-world adherence (defined as ≥4 hours/night for ≥70% of nights) ranges from 46–83% depending on the study. A treatment that reduces AHI by 70% but is used every night may deliver better outcomes than one that eliminates apneas but sits in the nightstand drawer.
Treatment Comparison Table
| Treatment | AHI Reduction | Best For | Compliance | Cost (est.) |
|---|---|---|---|---|
| CPAP | 95–100% | All severities | 50–60% long-term | $500–$1,500 + supplies |
| Oral appliance (MAD) | 50–70% | Mild–moderate OSA | 70–80% | $1,500–$3,000 |
| Positional therapy | 50–60% (if positional) | Supine-predominant OSA | Variable | $50–$300 |
| Weight loss (10%+) | 30–50% | BMI >30 with OSA | Lifestyle dependent | Variable |
| Hypoglossal nerve stimulation (Inspire) | 68–79% | Moderate–severe, CPAP-intolerant | >90% | $30,000–$40,000 |
| UPPP surgery | 40–60% | Anatomical obstruction | N/A (one-time) | $6,000–$10,000 |
| MMA surgery | 85–95% | Severe OSA, craniofacial cause | N/A (one-time) | $40,000–$80,000 |
| Tirzepatide (Zepbound) | 55–63% AHI reduction | OSA + obesity (BMI ≥30); FDA-approved Oct 2024 | High (once-weekly injection) | $550–$650/mo list; $0–$100/mo with insurance |
Tirzepatide (Zepbound) for OSA: In October 2024, the FDA approved tirzepatide (Zepbound) as the first GLP-1/GIP medication specifically indicated for moderate-to-severe obstructive sleep apnea in adults with obesity — based on the SURMOUNT-OSA trial. In SURMOUNT-OSA (Jens Mikkelsen et al., NEJM 2024), participants taking tirzepatide 10–15 mg weekly for 52 weeks achieved a median AHI reduction of 55–63% compared to 6–9% with placebo. Approximately 42% of tirzepatide-treated patients achieved OSA remission (AHI <5 events/hr). Body weight loss averaged 18–20%, which is the primary mechanism — reduced fat deposits around the airway and hypopharynx. Tirzepatide does not directly replace CPAP for severe OSA, but it may allow some patients to step down to oral appliance therapy or improve CPAP adherence by reducing nasal congestion and airway fat burden.
CPAP: The Gold Standard
Continuous positive airway pressure (CPAP) delivers pressurized air through a mask to splint the airway open. It eliminates nearly 100% of apneas and hypopneas when used correctly. Pros: Most effective, works for all severities, adjustable pressure, covered by most insurance. Cons: Mask discomfort, air leaks, nasal congestion, claustrophobia, noise, and the #1 issue — adherence. Auto-titrating (APAP) machines that adjust pressure in real-time have improved comfort over fixed-pressure devices.
Oral Appliances: The Compliance Winner
Mandibular advancement devices (MADs) reposition the lower jaw forward 6–10mm during sleep, enlarging the airway. While less effective than CPAP at reducing AHI, higher compliance rates (70–80% vs. 50–60%) mean real-world effectiveness is comparable for mild-to-moderate OSA. A 2015 JAMA study found equivalent cardiovascular outcomes between CPAP and oral appliances in mild-to-moderate OSA. Custom devices from a dental sleep medicine specialist significantly outperform over-the-counter options.
Surgical Options
Uvulopalatopharyngoplasty (UPPP): Removes excess tissue from the soft palate, uvula, and pharynx. Success rates of 40–60% AHI reduction. Significant post-operative pain. Best for patients with clearly identified palatal obstruction.
Maxillomandibular advancement (MMA): Moves both upper and lower jaws forward, dramatically expanding the airway. Success rates of 85–95%, comparable to CPAP. Major surgery with 4–6 week recovery. Reserved for severe cases or those with craniofacial anatomy contributing to obstruction.
Inspire (hypoglossal nerve stimulation): An implanted device stimulates the hypoglossal nerve to move the tongue forward during sleep. FDA-approved for moderate-to-severe OSA in CPAP-intolerant patients with BMI <35 and no complete concentric palatal collapse. STAR trial showed 68% median AHI reduction at 5 years.
Sleep Apnea Treatment Cost Breakdown
Out-of-pocket and insurance costs vary widely. Below are 2024 estimates based on Medicare reimbursement rates, Aetna/BCBS network pricing, and manufacturer list prices.
| Treatment | Typical Insurance Coverage | Out-of-Pocket (Uninsured) | Ongoing Annual Cost |
|---|---|---|---|
| CPAP (AutoPAP) | Covered with AHI ≥5 dx; 80–90% after deductible | $500–$1,500 device; $150–$350/yr supplies | $200–$500 (supplies: mask, tubing, filters) |
| Oral appliance (MAD) | Increasingly covered (up to $1,500–$2,500) with CPAP-intolerance documentation | $1,500–$3,000 | $100–$300 (adjustments, replacements) |
| Positional therapy device | Not typically covered | $50–$300 | $0–$50 |
| Inspire implant | Covered by most major plans for qualifying patients (BMI <35, AHI 15–65, CPAP-intolerant) | $30,000–$40,000 (without insurance) | $0 (battery replacement ~$15,000 at 11 years) |
| UPPP surgery | Covered when medically necessary with OSA diagnosis | $6,000–$10,000 | $0 |
| MMA surgery | Covered by some plans for severe OSA; often requires appeal | $40,000–$80,000 | $0 |
| Tirzepatide (Zepbound for OSA) | Covered by some plans for OSA + obesity indication (FDA Oct 2024); prior auth required | $550–$650/month ($6,600–$7,800/yr) | Ongoing while on medication; weight regain likely if stopped |
Cost-effectiveness perspective: For a CPAP-intolerant patient with severe OSA and obesity (BMI ≥30), tirzepatide may have comparable long-term cost to Inspire over 5 years ($33,000–$39,000) while delivering systemic metabolic benefits beyond AHI reduction. However, tirzepatide requires indefinite use for sustained effect; Inspire's cost is largely front-loaded. Many patients with insurance find CPAP + oral appliance the lowest out-of-pocket path; Inspire is the lowest effort long-term for surgical candidates.
Frequently Asked Questions
What is the most effective treatment for sleep apnea?
CPAP is the most effective at reducing AHI (95–100% elimination of events) and remains the gold standard for moderate-to-severe OSA. However, effectiveness depends on adherence. For mild-to-moderate OSA, oral appliances achieve comparable real-world outcomes due to higher compliance. MMA surgery approaches CPAP efficacy (85–95%) for severe cases.
What can I use instead of CPAP?
Alternatives include: oral appliances (mandibular advancement devices), positional therapy (for supine-predominant OSA), weight loss (10%+ body weight can reduce AHI by 30–50%), Inspire hypoglossal nerve stimulation (for moderate-severe, CPAP-intolerant patients who qualify), and surgical options. The best alternative depends on your OSA severity, anatomy, and BMI.
Does insurance cover sleep apnea treatment?
Most insurance plans cover CPAP equipment and supplies with a confirmed sleep apnea diagnosis (AHI ≥5). Oral appliances are increasingly covered, especially when documented CPAP intolerance is demonstrated. Inspire and surgical treatments are covered by many plans for qualifying patients. Check your specific plan for coverage details and pre-authorization requirements.
Topic updates
Get the weekly recovery roundup
Sleep, HRV, fatigue, burnout, cortisol rhythm, sleep apnea, overtraining, and stress physiology.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Continue Reading
-
Sleep apnea, fatigue, weight gain, and metabolic risk
Connect sleep apnea to fatigue, weight gain, testing, and treatment options.
-
Chronic fatigue: causes beyond just sleep
Causes of persistent fatigue beyond sleep — iron, thyroid, inflammation.
-
Sleep apnea symptoms: signs you're not breathing at night
OSA warning signs: snoring, witnessed apneas, daytime sleepiness.
-
Waking up tired every day? Here's why
Why 7-8 hours isn't enough when sleep quality is poor.
-
Sleep inertia: why you feel groggy when you wake up
Morning grogginess — circadian, cortisol, and sleep-stage causes.
-
Afternoon energy crash: causes and how to prevent it
The 2-4 PM slump: blood sugar, cortisol, and circadian factors.
-
Chronic fatigue syndrome (ME/CFS): what we know
ME/CFS: diagnostic criteria, current research, and management.
-
Poor sleep quality: root causes and evidence-based fixes
Root causes and evidence-based fixes beyond sleep hygiene.
-
Low HRV: what it means and how to improve it
What low HRV means and how to improve autonomic recovery.
-
Cortisol and sleep: how stress hormones wreck your rest
The cortisol-melatonin axis and 'wired but tired' patterns.